ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.131,97
0,32%
S&P 500
5.487,03
0,25%
Dow Jones
38.834,86
0,15%
Euro vs US Dollar
1,07397
-0,01%
Bitcoin
64.507,94
-2,97%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Fulgent Genetics Inc (FLGT)

  7. Fulgent Genetics Inc (FLGT) News

FLGT

Fulgent Genetics (FLGT)

Fulgent Genetics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:FLGT
DatumZeitQuelleÜberschriftSymbolFirma
04/06/202422h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
04/06/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
03/06/202414h00Business WireFulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck CancerNASDAQ:FLGTFulgent Genetics Inc
28/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
28/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
24/05/202414h00Business WireFulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual MeetingNASDAQ:FLGTFulgent Genetics Inc
21/05/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
21/05/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
16/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FLGTFulgent Genetics Inc
14/05/202422h05Business WireMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer TherapeuticsNASDAQ:FLGTFulgent Genetics Inc
07/05/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
03/05/202413h00Business WireFulgent Reports First Quarter 2024 Financial ResultsNASDAQ:FLGTFulgent Genetics Inc
11/04/202422h05Business WireFulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024NASDAQ:FLGTFulgent Genetics Inc
05/03/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
05/03/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
29/02/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
29/02/202401h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
28/02/202413h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FLGTFulgent Genetics Inc
28/02/202413h00Business WireFulgent Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FLGTFulgent Genetics Inc
28/02/202400h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
28/02/202400h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
13/02/202414h00Business WireFulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024NASDAQ:FLGTFulgent Genetics Inc
10/02/202400h09Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
09/02/202414h31PR Newswire (US)Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic TestingNASDAQ:FLGTFulgent Genetics Inc
07/02/202401h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
01/02/202422h39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
30/01/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
30/01/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
14/12/202302h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FLGTFulgent Genetics Inc
13/12/202303h43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FLGTFulgent Genetics Inc
 Showing the most relevant articles for your search:NASDAQ:FLGT

Kürzlich von Ihnen besucht

NYSE
NKE
Nike
TG
432
Arbor Metals
NYSE
DIS
Walt Disney
DBI
DAX
DAX
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
FX
EURJPY
Euro vs Yen
TG
ALV
Allianz
FX
EURGBP
Euro vs Sterling
AMEX
XLV
Health Care Select Sector
TG
RHM
Rheinmetall
TG
LHA
Deutsche Lufthansa
NASDAQ
NVDA
NVIDIA
TG
DBK
Deutsche Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten